Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
At UCB we are whole-heartedly committed to empowering patients, raising awareness and improving patient care and outcomes. Find out more https://t.co/Oz4a6MVaKC
— UCB News (@ucb_news) 18.05.2021 -
The pandemic is a massive crisis. It’s hitting young people particularly hard. We want to help them deal with their emotional difficulties. Our 2nd call for projects for our UCB Community Health Fund focuses on the mental health of vulnerable young people
— UCB News (@ucb_news) 17.05.2021 -
???? It's that time again! Check out our third wave of speakers that have been confirmed for the #ImmunologySummit2021 Register for FREE!
— UCB News (@ucb_news) 17.05.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
